The consortium aims to isolate and characterize all tumor cells circulating in blood to enable a real-time liquid biopsy for all cancer patients with metastatic disease. In September 2015 the annual meeting of the CTCTrap program was held in Estonia (www.utwente.nl/tnw/ctctrap/). After review of the tools evaluated and developed within the consortium a pilot study was conducted resulting in the study design shown in the diagram below. CTCTrap will enroll breast and prostate cancer patients into this study. A similar approach will be taken in CANCER-ID (http://www.cancer-id.eu/) in which Non-Small Cell Lung Cancer will be enrolled. An 18 ml aliquot is still available to evaluate alternative approaches for CTC isolation. An uniform CTC definition will be used across platforms making use of the Open-Source ACCEPT program under development in the CTCTrap and CANCER-ID consortiums.

For more information on CTCTrap please visit our website: www.tnw.utwente.nl/ctctrap or contact mcbp@tnw.utwente.nl